The short version of melanocortin receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-23. Anything still debated is marked as such rather than presented as settled.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
=== Excess heat and energy production === An excess heat observation is based on an energy balance. Various sources of energy input and output are continuously measured. Under normal conditions, the energy input can be matched to the energy output to within experimental error. In experiments such as those run by Fleischmann and Pons, an electrolysis cell operating steadily at one temperature transitions to operating at a higher temperature with no increase in applied current. If the higher temperatures were real, and not an experimental artifact, the energy balance would show an unaccounted term. In the Fleischmann and Pons experiments, the rate of inferred excess heat generation was in the range of 10–20% of total input, though this could not be reliably replicated by most researchers. Researcher Nathan Lewis discovered that the excess heat in Fleischmann and Pons's original paper was not measured, but estimated from measurements that didn't have any excess heat. Unable to produce excess heat or neutrons, and with positive experiments being plagued by errors and giving disparate results, most researchers declared that heat production was not a real effect and ceased working on the experiments. In 1993, after their original report, Fleischmann reported "heat-after-death" experiments—where excess heat was measured after the electric current supplied to the electrolytic cell was turned off. This type of report has also become part of subsequent cold fusion claims.
Human-animal chimeras include humans having undergone non-human to human xenotransplantation, which is the transplantation of living cells, tissues or organs from one species to another. Patient derived xenografts are created by xenotransplantation of human tumor cells into immunocompromised mice, and is a research technique frequently used in pre-clinical oncology research.
== Indications and uses == Glycated hemoglobin testing is recommended for both checking the blood sugar control in people who might be prediabetic and monitoring blood sugar control in patients with more elevated levels, termed diabetes mellitus. For a single blood sample, it provides far more revealing information on glycemic behavior than a fasting blood sugar value. However, fasting blood sugar tests are crucial in making treatment decisions. The American Diabetes Association guidelines are similar to others in advising that the glycated hemoglobin test be performed at least twice a year in patients with diabetes who are meeting treatment goals (and who have stable glycemic control) and quarterly in patients with diabetes whose therapy has changed or who are not meeting glycemic goals. Glycated hemoglobin measurement is not appropriate where a change in diet or treatment has been made within six weeks. Likewise, the test assumes a normal red blood cell aging process and mix of hemoglobin subtypes (predominantly HbA in normal adults). Hence, people with recent blood loss, hemolytic anemia, or genetic differences in the hemoglobin molecule (hemoglobinopathy) such as sickle-cell disease and other conditions, as well as those who have donated blood recently, are not suitable for this test. Due to glycated hemoglobin's variability, additional measures should be checked in patients at or near recommended goals.
Similar to acetylation. Instead of a simple methyl group, the myristoyl group has a tail of 14 hydrophobic carbons, which make it ideal for anchoring proteins to cellular membranes. The C-terminal carboxylate group of a polypeptide can also be modified, e.g.,
Thiopental is a barbiturate with one of the C=O double bonds (with the carbon being labelled 2 in the adjacent diagram) replaced with a C=S double bond, R1 being CH2CH3 (ethyl) and R3) being CH(CH3)CH2CH2CH3 (sec-pentyl). Thiopental is no longer available in the United States.
Sources: en.wikipedia.org
== Adverse effects == The US Food and Drug Administration label for the use of inotuzumab ozagamicin carries a boxed warning concerning the risk of liver toxicity, in particular hepatic veno-occlusive disease, which has been fatal in some people. The risk of this is higher in people who take the drug before having hematopoietic stem cell transplantation and more people die who have hematopoietic stem cell transplantation following treatment with this drug, than people who have hematopoietic stem cell transplantation, taking other chemotherapies. The risk gets higher as more rounds of treatment with inotuzumab ozogamicin are administered. The most common serious adverse reactions in people taking the drug in the clinical trial leading to approval include infections (23%), loss of neutrophils with fever (11%), hemorrhage (5%), stomach pain (3%), fever (3%), VOD (2%), and tiredness (2%). More than 20% of people had the following adverse reactions: loss of platelets (51%), loss of neutrophils (49%), infections (48%), anemia (36%), leukopenia (35%), tiredness (35%), hemorrhage (33%), fever (32%), nausea (31%), headache (28%), loss of neutrophils with fever (26%), elevated transaminases (26%), stomach pain (23%), and jaundice (21%). Between 10% and 20% of people also had loss of appetite, vomiting, diarrhea, mouth sores, constipation, chills, and injection site reactions. In studies in pregnant animals, the drug caused harm to the fetus at doses less than those used clinically, and so the drug has not been tested in pregnant women.
== Factors that affect BV == The determination of BV is carefully designed to accurately measure some aspects of protein usage whilst eliminating variation from other aspects. When using the test (or considering BV values) care must be taken to ensure the variable of interest is quantified by BV. Factors which affect BV can be grouped into properties of the protein source and properties of the species or individual consuming the protein.
The oxides B2O3, SiO2, GeO2, As2O3, and Sb2O3 readily form glasses. TeO2 forms a glass but this requires a "heroic quench rate" or the addition of an impurity; otherwise the crystalline form results. These compounds are used in chemical, domestic, and industrial glassware and optics. Boron trioxide is used as a glass fibre additive, and is also a component of borosilicate glass, widely used for laboratory glassware and domestic ovenware for its low thermal expansion. Most ordinary glassware is made from silicon dioxide. Germanium dioxide is used as a glass fibre additive, as well as in infrared optical systems. Arsenic trioxide is used in the glass industry as a decolourizing and fining agent (for the removal of bubbles), as is antimony trioxide. Tellurium dioxide finds application in laser and nonlinear optics. Amorphous metallic glasses are generally most easily prepared if one of the components is a metalloid or "near metalloid" such as boron, carbon, silicon, phosphorus or germanium. Aside from thin films deposited at very low temperatures, the first known metallic glass was an alloy of composition Au75Si25 reported in 1960. A metallic glass having a strength and toughness not previously seen, of composition Pd82.5P6Si9.5Ge2, was reported in 2011. Phosphorus, selenium, and lead, which are less often recognised as metalloids, are also used in glasses. Phosphate glass has a substrate of phosphorus pentoxide (P2O5), rather than the silica (SiO2) of conventional silicate glasses. It is used, for example, to make sodium lamps.
== Personal life == In January 2025, Heppell married his long-time partner, Kate. The couple hyphenated their surname to Turner-Heppell to acknowledge Kate's maiden name. In November and December 2025, Dyson competed on the twelfth season of I'm a Celebrity...Get Me Out of Here!, which began airing on January 18, 2026. He was eliminated on February 11, 2026 after 15 days in the jungle.
Sources: en.wikipedia.org
The fucoxanthin dinophyte lineages (including Karlodinium and Karenia) lost their original red algal derived chloroplast, and replaced it with a new chloroplast derived from a haptophyte endosymbiont, making these tertiary plastids. Karlodinium and Karenia probably took up different endosymbionts. Because the haptophyte chloroplast has four membranes, tertiary endosymbiosis would be expected to create a six membraned chloroplast, adding the haptophyte's cell membrane and the dinophyte's phagosomal vacuole. However, the haptophyte was heavily reduced, stripped of a few membranes and its nucleus, leaving only its chloroplast (with its original double membrane), and possibly one or two additional membranes around it. Fucoxanthin-containing chloroplasts are characterized by having the pigment fucoxanthin (actually 19′-hexanoyloxy-fucoxanthin and/or 19′-butanoyloxy-fucoxanthin) and no peridinin. Fucoxanthin is also found in haptophyte chloroplasts, providing evidence of ancestry.
Unlike the other Warsaw Pact leaders, Ceaușescu had not been slavishly pro-Soviet but rather had pursued an "independent" foreign policy; Romanian forces did not join their Warsaw Pact allies in putting an end to the Prague Spring—an invasion Ceaușescu openly denounced—while Romanian athletes competed at the Soviet-boycotted 1984 Summer Olympics in Los Angeles (receiving a standing ovation at the opening ceremonies and proceeding to win 53 medals, trailing only the United States and West Germany in the overall count). Conversely, while Soviet Communist Party General Secretary Mikhail Gorbachev spoke of reform, Ceaușescu maintained a hard political line and cult of personality. The austerity programme started in 1981 and the widespread poverty it introduced made the Communist regime very unpopular. The austerity programmes were met with little resistance among Romanians and there were only a few strikes and labour disputes, of which the Jiu Valley miners' strike of 1977 and the Brașov Rebellion of November 1987 at the truck manufacturer Steagul Roșu were the most notable. In March 1989, several leading activists of the PCR criticised Ceaușescu's economic policies in a letter, but shortly thereafter he achieved a significant political victory: Romania paid off its external debt of about US$11,000,000,000 several months before the time that even the Romanian dictator expected. However, in the months following the austerity programme, shortages of goods remained the same as before.
Hypoglycemia is a condition that occurs when blood glucose levels decrease below normal, causing symptoms including anxiety, tremors, nausea, palpitations, confusion, and coma. Individuals with diabetes or other conditions that result in low blood sugar may carry glucose tablets, oral glucose gel, hard candy, or sugar packets to use when their blood sugar becomes too low. Severe low blood sugar can lead to confusion, coma, neurological damage and other potentially serious complications, making it unsafe to administer glucose by mouth. In these cases, dextrose (D-glucose) can be administered into a vein to quickly and directly raise blood glucose levels.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.